Floatz Rating
C38/100
Confidence
Indicative
Sponsor
Assistance Publique - Hôpitaux de Paris
Modality
monoclonal_antibody
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07213882CT.gov A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sezary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| dt-7012 (this asset) | Assistance Publique - Hôpitaux de Paris | Early P1 | C · 38 |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Prednisone | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Cyclosporin A | Ohio State University Comprehensive Cancer Center | P2 | BB |
| Mogamulizumab | Kyowa Kirin Co., Ltd. | P2 | B |
| Denileukin Diftitox | Eisai Inc. | P4 | B |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Vanderbilt University Medical Center | P4 | B |
| Resminostat | 4SC AG | P2 | B |
+32 more in the Sezary Syndrome cohort
Other indications for dt-7012
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer | — | P1/2 | CC · 40 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | Early P1 | C · 39 |
| Mycosis Fungoides | — | Early P1 | C · 38 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. dt-7012 in Sezary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dt-7012-sezary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →